Patents by Inventor Dieter Wiedenmayer

Dieter Wiedenmayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220306637
    Abstract: The present invention relates to novel imidazopyrazines of general formula A, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 29, 2022
    Inventors: Riccardo GIOVANNINI, Dieter WIEDENMAYER
  • Patent number: 11376258
    Abstract: The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: July 5, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Dieter Wiedenmayer
  • Publication number: 20220160725
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 26, 2022
    Inventors: Matthias ECKHARDT, Marina Kristina WILLWACHER, Juergen PRESTLE, Ferenc KONTES, Leo THOMAS, Christofer Siegfried TAUTERMANN, Dieter WIEDENMAYER
  • Publication number: 20210393644
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 23, 2021
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20210387963
    Abstract: Disclosed are phenyltetrazole derivatives of formula (I), wherein A, R1, R2, X, R?, R?, and n are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the phenyltetrazole derivatives for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: October 7, 2019
    Publication date: December 16, 2021
    Inventors: Dieter WIEDENMAYER, Andreas GOLLNER, Iain LINGARD, Holger WAGNER
  • Publication number: 20210369723
    Abstract: The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 2, 2021
    Inventors: Riccardo GIOVANNINI, Dieter WIEDENMAYER
  • Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Publication number: 20210292301
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 23, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Elke LANGKOPF, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • Publication number: 20210276976
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Inventors: Matthias ECKHARDT, Maude GIROUD, Camilla MAYER, Holger WAGNER, Dieter WIEDENMAYER
  • Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 10793522
    Abstract: The present invention relates to sulfonamides of formula (I) wherein A, R1, and R2 are as defined herein. Also disclosed are medicaments comprising the compounds of formula (I) and their use for the treatment of metabolic and/or cardiovascular diseases.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Kley, Stefan Kauschke, Alexander Pautsch, Dieter Wiedenmayer
  • Patent number: 10695334
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: June 30, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Andreas Gollner, Elke Langkopf, Holger Wagner, Dieter Wiedenmayer
  • Publication number: 20200123140
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200123141
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200121691
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200062708
    Abstract: The present invention relates to sulfonamides of formula (I) wherein A, R1, and R2 are as defined herein. Also disclosed are medicaments comprising the compounds of formula (I) and their use for the treatment of metabolic and/or cardiovascular diseases.
    Type: Application
    Filed: December 4, 2017
    Publication date: February 27, 2020
    Inventors: Joerg KLEY, Stefan KAUSCHKE, Alexander PAUTSCH, Dieter WIEDENMAYER
  • Publication number: 20200054617
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: August 14, 2019
    Publication date: February 20, 2020
    Inventors: Matthias ECKHARDT, Andreas GOLLNER, Elke LANGKOPF, Holger WAGNER, Dieter WIEDENMAYER
  • Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer